Recent Updates
Recently added Catalysts
NMRA Negative Sentiment Score: 20/100

NEUMORA THERAPEUTICS, INC. (NASDAQ: NMRA) INVESTOR ALERT: Investors With Large Losses in Neumora Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Tuesday, February 11, 2025 2 min read
Key Takeaway: Bernstein Liebhard LLP has announced a class action lawsuit against Neumora Therapeutics, Inc. for alleged misrepresentations made during its IPO. The lawsuit claims that the company failed to disclose known risks concerning its flagship drug candidate, Navacaprant, during the initial public offering in September 2023. Investors impacted by these misrepresentations are encouraged to take action by the April 7, 2025, deadline to file as lead plaintiffs. The law firm emphasizes that they operate on a contingency fee basis, allowing shareholders to pursue claims without upfront costs.

Market Sentiment Analysis

CONCERNS & RISKS

  • A securities class action lawsuit has been filed against Neumora for misrepresentations related to their IPO.
  • The lawsuit claims that the company did not disclose known risks regarding its Phase Three Program for its drug candidate, Navacaprant.
  • Investors suffered large losses due to the issues raised in the lawsuit.

Full Press Release Details

NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the stock of Neumora Therapeutics, Inc. (“Neumora” or the “Company”) pursuant and/or traceable to the offering documents issued in connection with the initial public offering (“IPO”) held on or about September 15, 2023.
For more information, submit a form at Neumora Therapeutics, Inc. Shareholder Class Action Lawsuits, email Investor Relations Manager Peter Allocco at pallocco@bernlieb.com, or call us at (212) 951-2030.
According to the lawsuit, Defendants made misrepresentations concerning risks and uncertainties known by the Company at the time of the IPO regarding the Phase Three Program for Navacaprant, its flagship drug candidate.
If you wish to serve as lead plaintiff for the Class, you must file papers by April 7, 2025. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.
ATTORNEY ADVERTISING. © 2025 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Investor Relations Manager
Bernstein Liebhard LLP
https://www.bernlieb.com
pallocco@bernlieb.com

Tags

neumora therapeutics
class action lawsuit

Frequently Asked Questions

What is the lawsuit against Neumora Therapeutics about?

The lawsuit claims Neumora misrepresented risks related to its IPO and drug candidate.

Who can serve as lead plaintiff in the class action?

Anyone interested must file papers by April 7, 2025, to become the lead plaintiff.

What are the fees for shareholders participating in the lawsuit?

All legal representation is on a contingency fee basis, with no fees for shareholders.

How has Bernstein Liebhard LLP performed in class actions?

Since 1993, they have recovered over $3.5 billion from successfully litigating class actions.

How can I contact Bernstein Liebhard LLP for more information?

You can email Peter Allocco at pallocco@bernlieb.com or call (212) 951-2030.

Tags: NMRA Viatris Investor Conferences Healthcare Neumora Therapeutics class action lawsuit Navacaprant investor rights
Last updated: Feb 11, 2025